Home » Case Studies » Commercial Strategic Planning » Impact Forecast of a Biomarker…

Impact Forecast of a Biomarker Strategy

CBPartners helped refine and forecast the impact of a biomarker strategy on the ulcerative colitis and Crohn’s space across various developmental options.


To explore a range of potential scenarios associated with the outcomes of a product biomarker analysis, including the impact on lift to uptake for each scenario to ultimately inform the overall commercial strategy in ulcerative colitis (UC) and Crohn’s Disease (CD).



Conduct n=30 qualitative discussions and focus groups with community gastroenterologists, pathologists, and Key Opinion Leaders (KOLs),  understand biomarker perceptions and explore tissue and blood biomarkers across specific dimensions that included efficacy, specificity, consistency, and others.


  • Clinician perceptions of predictive biomarker testing
  • Biomarker strategy impact on treatment selection across lines of therapy
  • Projected utilization rates across different biomarker scenarios
  • Recommendations to define biomarker strategy, monitor key risks / market evolution, and optimize uptake potential

Illustrative Outputs


Outputs helped define key risks and opportunities of the client’s biomarker strategy and directionally quantified the impact of each tested biomarker scenario on uptake potential.